Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tezepelumab (Primary) ; Omalizumab
  • Indications Chronic urticaria
  • Focus Therapeutic Use
  • Acronyms INCEPTION
  • Sponsors Amgen

    • Most Recent Events

    • 26 Feb 2024 Primary endpoint (Change from Baseline in Urticaria Activity Score over 7 days (UAS7) has not been met according to results presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 26 Feb 2024 Results of subgroup analysis assessing the effects of tezepelumab in a subgroup (anti-IgE naive) of CSU patients presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 27 Apr 2023 According to an Amgen media release, top-line data from this study anticipated in mid-2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top